TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02171936

Intervention type: OTHER
Intervention: Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).
Study: NCT00670475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam
Description: In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes.
Study: NCT02519283

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GUIDED-HF
Description: Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up.
Study: NCT03369886

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical Coherence Tomography Angiography (OCTA)
Description: The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical Coherence Tomography Angiography (OCTA)
Description: The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
Study: NCT04446013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optic Nerve Sheath Diameter Measurement
Description: The change in intracranial pressure via optic nerve sheath diameter measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optic Nerve Sheath Diameter Measurement
Description: The change in intracranial pressure via optic nerve sheath diameter measurement
Study: NCT02336568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytoine
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
Study: NCT03636802

Intervention type: OTHER
Intervention: Questionnaire BPI
Description: Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
Study: NCT00880854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG and CP-675,206
Description: Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15
Study: NCT03002948

Intervention type: OTHER
Intervention: Orgasm
Description: clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score
Study: NCT01531621

Intervention type: OTHER
Intervention: Biomarker sampling
Description: Blood samples every 8-12 weeks
Study: NCT01599533

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study: NCT04427202

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to harm reduction services
Description: Participants are referred to harm reduction services
Study: NCT02532621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous InterGraft Connector
Description: The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sutured arterial anastomosis of an implanted vascular graft for hemodialysis
Description: The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemodialysis
Description: The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
Study: NCT01566539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) 24 IU
Description: Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) 24 IU
Description: Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) 24 IU
Description: Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
Study: NCT03291977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescéine Sodique Faure
Description: Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White-light surgery
Description: The surgery will be performed under classical conditions
Study: NCT03108105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOS-C2001-B
Description: A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
Study: NCT01566539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) 24 IU
Description: Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP)
Description: Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP)
Description: Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
Study: NCT06693076

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
Study: NCT00748358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
Study: NCT01505465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
Study: NCT02355548

Intervention type: OTHER
Intervention: Outpatient Treatment of Pulmonary Embolism
Description: Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
Study: NCT01873768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: 1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ε-Aminocaproic Acid (EACA)
Description: 7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
Study: NCT03001609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
Study: NCT04935827

Intervention type: OTHER
Intervention: Season of Year
Description: We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November

Intervention type: OTHER
Intervention: Hospitalized 14 days prior to dialysis
Description: We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2
Study: NCT00514995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: 4.5 g/night - 9 g/night, liquid taken twice per night
Study: NCT04275947

Intervention type: OTHER
Intervention: nCapp, a cell phone-based auto-diagnosis system
Description: Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19

Intervention type: OTHER
Intervention: nCapp, a cell phone-based auto-diagnosis system
Description: Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
Study: NCT02504034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transhepatic portosystemic shunt
Description: Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6-French sheath

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-gauge chiba needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 260-cm-long stiff shaft wire
Study: NCT01566539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP) 40 IU
Description: Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
Study: NCT01213732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated inferior limb perfusion
Description: Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
Study: NCT03424057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Asymmetric Primary Closure and Additional Skin Excision Technique
Description: In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
Study: NCT02504034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered stent
Study: NCT04035837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa
Description: All the patients in this study will receive pegylated interferon for all course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa
Description: All the patients in this study will receive pegylated interferon for all course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa
Description: All the patients in this study will receive pegylated interferon for all course.
Study: NCT03662386

Intervention type: PROCEDURE
Intervention: OCT-A
Description: Optical coherence tomography angiography (OCT-A)
Study: NCT02282917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-42
Description: AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
Study: NCT01001637

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin Formulation
Description: 2000mg or 3000mg daily BID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00794911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy
Description: 8 weekly individual counseling sessions
Study: NCT03662386

Intervention type: PROCEDURE
Intervention: Visual acuity (ETDRS)
Description: Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
Study: NCT00497367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) TAXUS Petal
Description: TAXUS Petal, paclitaxel eluting stent
Study: NCT02581800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App group
Study: NCT02363751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.
Study: NCT01129999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
Study: NCT03184454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation
Description: Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety).
Study: NCT03331965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 5 MG/ML Injectable Solution
Description: A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
Study: NCT00794911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly individual counseling sessions
Study: NCT03027336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coleosoma
Description: patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will take one tablet daily for 12 weeks.
Study: NCT01171885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 20 ml of 0.9% saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of Ropivacaine 0.25%.
Study: NCT03338465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1, STORZ Medical, Switzerland with F-SW applicator
Description: The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1, STORZ Medical, Switzerland with F-SW applicator
Description: The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
Study: NCT02809092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells + Chemotherapy Starting
Description: Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.